Aerie Pharmaceuticals Inc. (NASDAQ:AERI) traded up 6.5% during trading on Monday . The company traded as high as $19.63 and last traded at $19.62, with a volume of 401,043 shares trading hands. The stock had previously closed at $18.43.

A number of equities research analysts have commented on the company. Zacks Investment Research upgraded Aerie Pharmaceuticals from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research report on Wednesday, April 20th. Brean Capital reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Monday, May 16th. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Tuesday, May 3rd. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $42.50.

The company’s 50 day moving average is $17.68 and its 200 day moving average is $16.00. The firm’s market cap is $541.94 million.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.02. Equities research analysts forecast that Aerie Pharmaceuticals Inc. will post ($2.74) earnings per share for the current year.

In related news, major shareholder Foresite Capital Fund Ii, L.P. bought 250,000 shares of the firm’s stock in a transaction on Friday, July 22nd. The stock was acquired at an average cost of $17.50 per share, for a total transaction of $4,375,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.